IN THE SPOTLIGHT

Third‐Generation EGFR‐TKIs in T790M‐Negative NSCLC After First/Second‐Generation EGFR‐TKI Failure: A Retrospective Study

Third‐Generation EGFR‐TKIs in T790M‐Negative NSCLC After First/Second‐Generation EGFR‐TKI Failure: A Retrospective Study

Zidesamtinib Provides Hope as New Option for ROS1+ NSCLC

Zidesamtinib Provides Hope as New Option for ROS1+ NSCLC

Emerging Targets in NSCLC beyond EGFR, ALK & ROS .pptx

Emerging Targets in NSCLC beyond EGFR, ALK & ROS .pptx

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial

Remarkable response to pembrolizumab in PD-L1 overexpressing (≥ 50%) NSCLC and extracranial abscopal effect induced by brain radiotherapy: a case report

Remarkable response to pembrolizumab in PD-L1 overexpressing (≥ 50%) NSCLC and extracranial abscopal effect induced by brain radiotherapy: a case report

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC

Aakash Desai: Updated OS From the Phase II PHAROS Study in BRAF V600E–Mutant NSCLC

Aakash Desai: Updated OS From the Phase II PHAROS Study in BRAF V600E–Mutant NSCLC